Tofacitinib fixed-dose regimens attained better kidney function and comparable efficacy to
cyclosporine (CsA) in kidney transplant patients, albeit with increased risks of certain
adverse events. This post-hoc analysis evaluated whether a patient subgroup with an
acceptable risk-benefit profile could be identified. Tofacitinib exposure was a statistically
significant predictor of serious infection rate. One-hundred and eighty six kidney transplant
patients were re-categorized to above-median (AME) or below-median (BME) exposure …